Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Agreement table at the dichotomous level for valid, non-missing results

From: Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples

mCRC samples (n = 182) therascreen KRAS RGQ PCR Kit
Idylla™ KRAS Mutation Test KRAS mutation KRAS Wild-type Totals
KRAS Mutation 79 5 84
KRAS Wild-type 1 97 98
Totals 80 102 182
  1. Overall agreement between therascreen and Idylla™ platform for detection of KRAS mutations. mCRC metastatic colorectal cancer. KRAS Wild type = no mutation detected